Heidi, the fast-growing healthcare AI company, announced its launch in Hong Kong, following its recent US$65 million Series B funding round led by Point72 Private Investments.
The expansion demonstrates Heidi’s commitment to the long-term development of its Hong Kong operations. It will invest in R&D and in building local teams across sales, implementation, and fostering clinical partnerships that drive sustainable growth in the healthcare sector. The new office will support customer growth, market enablement, and collaboration with healthcare providers.
As part of its entry, Heidi also announced a research partnership with the Hong Kong University of Science and Technology (HKUST) to advance the study of AI-powered clinical documentation. The collaboration will generate evidence to guide safe, scalable AI use in healthcare; enhancing efficiency, accuracy, and clinician wellbeing while positioning Hong Kong as a regional leader in AI-driven medical innovation.
